Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Our data indicate that the addition of ΔctDNA to baseline VIGex may refine prediction for IO.
Authors
- Lillian L. Siu (ORCID: https://orcid.org/0000-0002-3500-0540)
- Benjamin Haibe‐Kains (ORCID: https://orcid.org/0000-0002-7684-0079)
- Alberto Hernando‐Calvo (ORCID: https://orcid.org/0000-0002-1692-1125)
- S.Y. Cindy Yang (ORCID: https://orcid.org/0000-0001-9579-8462)
- Aaron R. Hansen (ORCID: https://orcid.org/0000-0002-2363-8707)
- Deborah Lo Giacco
- Zhihui Amy Liu (ORCID: https://orcid.org/0000-0003-1537-4868)
- Stéphanie Lheureux (ORCID: https://orcid.org/0000-0003-4405-5890)
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Elena Garralda (ORCID: https://orcid.org/0000-0002-4412-7842)
- Pamela S. Ohashi (ORCID: https://orcid.org/0000-0003-2915-9317)
- Farnoosh Abbas‐Aghababazadeh (ORCID: https://orcid.org/0000-0001-6427-9379)
- Scott V. Bratman (ORCID: https://orcid.org/0000-0001-8610-4908)
- Ming Han (ORCID: https://orcid.org/0000-0002-0136-2412)
- María Vila-Casadesús (ORCID: https://orcid.org/0000-0001-6597-7953)
- Ana Vivancos (ORCID: https://orcid.org/0000-0003-2888-6512)
- Trevor J. Pugh (ORCID: https://orcid.org/0000-0002-8073-5888)
- Roger Berché
- Sawako Elston (ORCID: https://orcid.org/0009-0006-2524-2630)
- Anna Spreafico (ORCID: https://orcid.org/0000-0002-3034-3042)
- Omar Saavedra (ORCID: https://orcid.org/0000-0003-4160-791X)
- Judith Matito
- A Hal K. Berman
- Alexey Aleshin
- Albiruni Abdul Razak
Institutions
- Ontario Institute for Cancer Research (CA)
- Universitat Autònoma de Barcelona (ES)
- University Health Network (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Natera (United States) (US)
- Vector Institute (CA)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/po.24.00100
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Eli Lilly and Company
- Gilead Sciences
- Natera
- Sociedad Española de Oncología Médica
- Merck Canada
- CRIS Cancer Foundation
- Genentech